Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer

被引:11
作者
Chao, Angel [1 ,2 ,3 ]
Chen, Shu-Jen [4 ]
Chen, Hua-Chien [4 ]
Tan, Kien Thiam [4 ]
Hsiao, Wen [4 ]
Jung, Shih-Ming [2 ,5 ]
Yang, Lan-Yan [6 ]
Huang, Kuan-Gen [1 ,2 ,3 ]
Chou, Hung-Hsueh [1 ,2 ,3 ]
Huang, Huei-Jean [1 ,2 ,3 ]
Chang, Ting-Chang [1 ,2 ,3 ]
Chao, An-Shine [1 ,2 ,7 ]
Lee, Yun-Hsien [8 ,9 ]
Wu, Ren-Chin [2 ,5 ]
Lai, Chyong-Huey [1 ,2 ,3 ]
机构
[1] Chang Gung Mem Hosp Linkou, Dept Obstet & Gynecol, 5 Fushin Str, Taoyuan 333, Taiwan
[2] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[3] Chang Gung Mem Hosp Linkou, Gynecol Canc Res Ctr, Taoyuan, Taiwan
[4] ACT Genom Co Ltd, Taipei, Taiwan
[5] Chang Gung Mem Hosp Linkou, Dept Pathol, 5 Fushin Str, Taoyuan 333, Taiwan
[6] Chang Gung Mem Hosp Linkou, Clin Trial Ctr, Biostat Unit, Taoyuan, Taiwan
[7] New Taipei City Municipal Tu Cheng Hosp, Dept Obstet & Gynecol, New Taipei, Taiwan
[8] Ming Chuan Univ, Dept Biotechnol, Taoyuan, Taiwan
[9] Chang Gung Mem Hosp Linkou, Genom Med Core Lab, Taoyuan, Taiwan
关键词
Circulating tumor DNA; Ovarian cancer; High-grade serous carcinoma; Clear cell carcinoma; CLEAR-CELL CARCINOMA; REVERSION;
D O I
10.1016/j.bj.2022.09.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: We investigated whether mutations in plasma circulating tumor DNA (ctDNA) can provide prognostic insight in patients with different histological types of ovarian carcinoma. We also examined the concordance of mutations detected in ctDNA samples with those identified in the corresponding formalin-fixed paraffin-embedded (FFPE) tumor specimens. Methods: Between July 2016 and December 2017, 29 patients with ovarian carcinoma were prospectively enrolled. FFPE tumor specimens were obtained from all participants. A total of 187 blood samples for ctDNA analysis were collected before surgery (C0), immediate after surgery before adjuvant chemotherapy (C1), and at six-month intervals. Progression free survival (PFS) and overall survival (OS) served as the main outcome measures. Results: The study cohort consisted of 13 (44.8%) patients with high-grade serous carcinomas (HGSC), 9 (31.0%) with clear cell carcinoma, 2 (6.9%) with mucinous carcinomas, 4 (13.8%) with low-grade serous carcinomas, and 1 (3.4%) with endometrioid carcinoma. Twenty-four (82.8%) patients had at least one detectable ctDNA variant. The concordance rate between mutations identified in pretreatment ctDNA and corresponding FFPE tumor specimens was 92.3% for patients with HGSC and 58.6% for the entire cohort. The median follow-up time was 33.15 months (range: 0.79-46.13 months). Patients with an advanced stage disease more likely had detectable ctDNA mutations before surgery (C0) and after surgery at C1, while those with HGSC more likely had ctDNA mutations detected before surgery. The presence of ctDNA mutations at C1 was an independent predictor of worse OS with a hazard ratio of 6.56 (95% confidence interval, (1.07-40.17) for detectable versus undetectable C1 ctDNA variants, p = 0.042). Conclusions: ctDNA mutations are common in patients with ovarian carcinoma. The presence of ctDNA mutations after surgery was an independent predictor of less favorable PFS and OS.
引用
收藏
页数:10
相关论文
共 49 条
[1]   Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma [J].
Arend, Rebecca C. ;
Londono, Angelina I. ;
Montgomery, Allison M. ;
Smith, Haller J. ;
Dobbin, Zachary C. ;
Katre, Ashwini A. ;
Martinez, Alba ;
Yang, Eddy S. ;
Alvarez, Ronald D. ;
Huh, Warner K. ;
Bevis, Kerri S. ;
Straughn, J. Michael, Jr. ;
Estes, Jacob M. ;
Novak, Lea ;
Crossman, David K. ;
Cooper, Sara J. ;
Landen, Charles N. ;
Leath, Charles A., III .
MOLECULAR CANCER RESEARCH, 2018, 16 (05) :813-824
[2]   Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? [J].
Asante, Du-Bois ;
Calapre, Leslie ;
Ziman, Melanie ;
Meniawy, Tarek M. ;
Gray, Elin S. .
CANCER LETTERS, 2020, 468 :59-71
[3]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[4]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[5]   Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy [J].
Chan, Hiu Ting ;
Nagayama, Satoshi ;
Chin, Yoon Ming ;
Otaki, Masumi ;
Hayashi, Rie ;
Kiyotani, Kazuma ;
Fukunaga, Yosuke ;
Ueno, Masashi ;
Nakamura, Yusuke ;
Low, Siew-Kee .
MOLECULAR ONCOLOGY, 2020, 14 (08) :1719-1730
[6]   Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers [J].
Chan, John K. ;
Teoh, Deanna ;
Hu, Jessica M. ;
Shin, Jacob Y. ;
Osann, Kathryn ;
Kapp, Daniel S. .
GYNECOLOGIC ONCOLOGY, 2008, 109 (03) :370-376
[7]   Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities [J].
Cheasley, Dane ;
Nigam, Abhimanyu ;
Zethoven, Magnus ;
Hunter, Sally ;
Etemadmoghadam, Dariush ;
Semple, Timothy ;
Allan, Prue ;
Carey, Mark S. ;
Fernandez, Marta L. ;
Dawson, Amy ;
Kobel, Martin ;
Huntsman, David G. ;
Le Page, Cecile ;
Mes-Masson, Anne-Marie ;
Provencher, Diane ;
Hacker, Neville ;
Gao, Yunkai ;
Bowtell, David ;
deFazio, Anna ;
Gorringe, Kylie L. ;
Campbell, Ian G. .
JOURNAL OF PATHOLOGY, 2021, 253 (01) :41-54
[8]   Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan [J].
Chiang, Ying-Cheng ;
Chen, Chi-An ;
Chiang, Chun-Ju ;
Hsu, Tsui-Hsia ;
Lin, Ming-Chieh ;
You, San-Lin ;
Cheng, Wen-Fang ;
Lai, Mei-Shu .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (04) :342-351
[9]   Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial [J].
Chou, Hung-Hsueh ;
Chen, Wei-Chun ;
Yang, Lan-Yan ;
Huang, Huei-Jean ;
Chang, Wei-Yang ;
Lin, Hao ;
Wu, Ren-Chin ;
Chen, Min-Yu ;
Qiu, J. Timothy ;
Huang, Kuan-Gen ;
Chao, Angel ;
Chang, Ting-Chang ;
Lai, Chyong-Huey .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2021, 262 :13-20
[10]   Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer [J].
Christie, Elizabeth L. ;
Fereday, Sian ;
Doig, Ken ;
Pattnaik, Swetansu ;
Dawson, Sarah-Jane ;
Bowtell, David D. L. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (12) :1274-1280